Ambit Biosciences has raised $300 million in new venture capital. The funding round was led by independent investment firm Apposite Capital.

The company’s existing investors, including Perseus-Soros Biopharmaceutical Fund and OrbiMed Advisors, also participated. The funding will allow the biopharmaceutical company to continue the clinical development of its products.

Click here for the release from Business Wire.